Back to Search
JOSHUA BYRD, DMD
DMD
Dentist
NPI: 1922693449Individual
Specialties, Licenses & Credentials
DentistPrimary
Dentist
Code: 122300000X
12534(NC)
Research & Publications (20)
"It's safe to ask": promoting patient safety through health literacy.
PMID 18382168·Healthc Q·2008
8-other
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
PMID 17003373·Blood·2007
3-trial
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
PMID 17671129·Clin Cancer Res·2007
3-trial
Missouri's experiment to increase quality--and decrease costs.
PMID 16669321·Behav Healthc·2006
8-other
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
PMID 16616068·Semin Oncol·2006
6-review
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
PMID 16344317·J Clin Oncol·2006
8-other
Laser seeding of the storage-ring microbunching instability for high-power coherent terahertz radiation.
PMID 17026236·Phys Rev Lett·2006
8-other
Tailored terahertz pulses from a laser-modulated electron beam.
PMID 16712239·Phys Rev Lett·2006
8-other
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
PMID 15466934·Blood·2005
3-trial
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
PMID 15930354·Clin Cancer Res·2005
3-trial
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
PMID 15138165·Blood·2005
4-observational
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
PMID 15020610·J Clin Oncol·2004
3-trial
Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
PMID 12517774·Cancer Res·2003
8-other
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
PMID 12393429·Blood·2003
3-trial
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
PMID 12592330·Leukemia·2003
3-trial
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
PMID 11807010·Blood·2002
3-trial
Observation of broadband self-amplified spontaneous coherent terahertz synchrotron radiation in a storage ring.
PMID 12485072·Phys Rev Lett·2002
8-other
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
PMID 12393746·Blood·2002
3-trial
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
PMID 11378265·Exp Hematol·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 ERWIN RD
DUNN, NC 28334 - Phone
- (910) 891-5000
Quick Facts
- NPI
- 1922693449
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile